{"url":"https://lda.gov/api/v1/filings/a2932449-d86b-4bf4-8b97-72e156da7087/","filing_uuid":"a2932449-d86b-4bf4-8b97-72e156da7087","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2025,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/a2932449-d86b-4bf4-8b97-72e156da7087/print/","filing_document_content_type":"text/html","income":null,"expenses":"650000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Beth Anne Cole","dt_posted":"2025-04-16T18:37:15-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 New Jersey Ave NW","registrant_address_2":"Suite 850","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":16032,"url":"https://lda.gov/api/v1/registrants/16032/","house_registrant_id":31463,"name":"ASSOCIATION FOR ACCESSIBLE MEDICINES","description":"Association representing the interests of the generic pharmaceutical industry.","address_1":"601 New Jersey Ave NW","address_2":"Suite 850","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MARK RATNER","contact_telephone":"+1 202-249-7100","dt_updated":"2026-07-29T08:15:25.555128-04:00"},"client":{"id":121533,"url":"https://lda.gov/api/v1/clients/121533/","client_id":12,"name":"ASSOCIATION FOR ACCESSIBLE MEDICINES","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-01-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription Drug Costs. H.R.1843 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: A bill to provide for increased transparency in generic drug applications. H.R.1396: To amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes. Drug Shortages. Biosimilar Interchangeability. H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. E-Labeling.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66451,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73046,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"RAAB","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare Part D Reform. H.R._/S._: Ensuring Access to Lower-Cost Medicines for Seniors Act. H.R._/S._: Increasing Access to Biosimilars Act. Medicaid Rebate Penalty.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66451,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73046,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"RAAB","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"H.R._/S._: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R._/S._: Patent Eligibility Restoration Act. H.R._/S._: To address patent thickets. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. S._: A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. S.43: Skinny Labels, Big Savings Act. S.1040: Drug Competition Enhancement Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73046,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"RAAB","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":64,"name":"Federal Trade Commission (FTC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"General Trade Issues. Drug Supply Chain. Country of Origin Labeling. Tariffs on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73046,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"RAAB","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}